Director/PDMR Shareholding

RNS Number : 0567Q

GSK PLC

15 February 2023

 

GSK plc (the ' Company ')

Vesting of Deferred Bonus Awards under the Deferred Annual Bonus Plan and Sale of Ordinary Shares

This notification sets out the vesting details for Persons Discharging Managerial Responsibilities ('PDMRs') of Deferred Bonus Awards over Ordinary Shares made in 2020 under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan ('DABP') and subsequent sale of Ordinary Shares to meet tax liabilities. In accordance with the shareholder approved 2017 Remuneration Policy and the DABP rules, the awards comprised a mandatory bonus deferral only. The three-year restricted period for the awards commenced on 14 February 2020 and ended on 14 February 2023.  Dividends accrued on the awards during the restricted period. The awards were granted in 2020 as nil-cost options over Ordinary Shares.

The closing price of Ordinary Shares of GSK plc on 14 February 2023 was £14.70.

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms E Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	60,707
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms E Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8730	28,576
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr I Mackay
b)	Position/status	Chief Financial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	40,985
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr I Mackay
b)	Position/status	Chief Financial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8887	19,292
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms D Conrad
b)	Position/status	Chief People Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	7,893
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms D Conrad
b)	Position/status	Chief People Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8743	4,240
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr J Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	11,259
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr J Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8628	5,305
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms S Jackson
b)	Position/status	SVP, Global Communications and CEO Office
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	4,796
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms S Jackson
b)	Position/status	SVP, Global Communications and CEO Office
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8804	2,263
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr L Miels
b)	Position/status	Chief Commercial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	18,375
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr L Miels
b)	Position/status	Chief Commercial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8830	1,171
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D Redfern
b)	Position/status	President Corporate Development
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	13,471
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D Redfern
b)	Position/status	President Corporate Development
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8750	6,348
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr R Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	9,539
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr R Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8756	4,500
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr P Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	7,779
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr P Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8772	3,669
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

 

END

 

 

DSHSFFFMIEDSESE